SUBLIMAZE is a brand name for Fentanyl. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Sublimaze is an opioid analgesic used: a. In low doses to provide analgesia during short surgical procedures. b. In high doses as an analgesic/respiratory depressant in patients requiring assisted ventilation. c. In combination with a neuroleptic in the technique of neuroleptanalgesia. d. In the treatment of severe…
Verbatim from this product's MHRA label. Tap a section to expand.
4). Route of administration Intravenous administration either as a bolus or by infusion. Intramuscular administration. Fentanyl should be given only in an environment where the airway can be controlled and by personnel who can control the airway (see section
The safety of fentanyl IV was evaluated in 376 subjects who participated in 20 clinical trials evaluating fentanyl IV as an anaesthetic. These subjects took at least 1 dose of fentanyl IV and provided safety data. 3). Including the above-mentioned adverse reactions, Table 1 displays adverse reactions that have been reported with the use of fentanyl IV from either clinical trials or postmarketing experience.
The displayed frequency categories use the following convention:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available clinical trial data). 4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.
4 Special warnings and precautions). To avoid bradycardia, it is recommended to administer a small intravenous dose of an anti-cholinergic just before anaesthetic induction. 6 Special precautions for disposal and other handling). Posology Sublimaze, by the intravenous route, can be administered to both adults and children.
The dose of Sublimaze should be individualised according to age, body weight, physical status, underlying pathological condition, use of other drugs and type of surgery and anaesthesia.
Adults The usual dosage regimen in adults is as follows:
Initial Supplemental Spontaneous Respiration 50-200 mcg 50 mcg Assisted Ventilation 300-3500 mcg 100-200 mcg Doses in excess of 200 mcg are for use in anaesthesia only. As a premedicant, 1-2 ml Sublimaze may be given intramuscularly 45 minutes before induction of anaesthesia.
After intravenous administration in unpremedicated adult patients, 2 ml Sublimaze may be expected to provide sufficient analgesia for 10-20 minutes in surgical procedures involving low pain intensity. 10 ml Sublimaze injected as a bolus gives analgesia lasting about one hour.
The analgesia produced is sufficient for surgery involving moderately painful procedures. Giving a dose of 50 mcg/kg Sublimaze will provide intense analgesia for some four to six hours, for intensely stimulating surgery. Sublimaze may also be given as an infusion.
1 mcg/kg/min. Alternatively the loading dose of Sublimaze may be given as a bolus. Infusion rates should be titrated to individual patient response; lower infusion rates may be adequate. Unless it is planned to ventilate post-operatively, the infusion should be terminated at about 40 minutes before the end of surgery.
g. 08 mcg/kg/minute are necessary if spontaneous ventilation is to be maintained. Higher infusion rates (up to 3 mcg/kg/minute) have been used in cardiac surgery. Sublimaze is chemically incompatible with the induction agents thiopentone and methohexitone because of wide differences in pH.
1 or other opioids. Respiratory depression, obstructive airways disease. Concurrent administration with monoamine oxidase inhibitors, or within 2 weeks of their discontinuation.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Fentanyl in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Paediatric population Children aged 12 to 17 years old:
Follow adult dosage. 4).
Use in elderly and debilitated patients:
As with other opioids, the initial dose should be reduced in the elderly ( >65 years of age) and in debilitated patients. The effect of the initial dose should be taken into account in determining supplemental doses.
Obese patients:
In obese patients there is a risk of overdosing if the dose is calculated based on body weight. Obese patients should have dosage calculated according to their estimated lean body mass. 2 Pharmacokinetic properties). 1 or other opioids.
Respiratory depression, obstructive airways disease. Concurrent administration with monoamine oxidase inhibitors, or within 2 weeks of their discontinuation. 4 Special warnings and precautions for use Warnings: Tolerance and Opioid use disorder (abuse and dependence) Tolerance, physical dependence, and psychological dependence may develop upon repeated administration of opioids Repeated use of opioids may lead to Opioid use disorder (OUD).
Abuse or intentional misuse of opioids may result in overdose and/or death. g. major depression, anxiety and personality disorders). For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses.
, major depression). Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse. A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers.
These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient. Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction. The clinical […]